The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Do tumor necrosis factor inhibitors cause uveitis? A registry‐based study
Abstract
Objective: Population‐based studies of patients with ankylosing spondylitis indicate that tumor necrosis factor (TNF) inhibitors prevent uveitis. Paradoxically, anecdotal reports implicate etanercept as a cause of uveitis. Therefore, using the information from 2 drug events databases, the purpose of this study was to assess reported cases of uveitis associated with the use of TNF inhibitors. Methods: Uveitis cases occurring in the US associated with etanercept, infliximab, or adalimumab therapy that were reported to 2 spontaneous reporting databases prior to January 1, 2006 were reviewed. Results: Overall, there were 43 cases of uveitis associated with etanercept, 14 associated with infliximab, and 2 associated with adalimumab. After normalizing for the estimated number of patients treated with each medication, etanercept was associated with a greater number of uveitis cases than infliximab (P < 0.001) and adalimumab (P < 0.01), while no such association was found between adalimumab and infliximab (P > 0.5). Using a priori criteria to avoid including patients whose underlying disease was associated with uveitis, 20 cases associated with etanercept, 4 cases associated with infliximab, and 2 cases associated with adalimumab were identified. A repeat analysis again revealed a greater number of uveitis cases associated with etanercept (P < 0.001 versus infliximab). Conclusion: Etanercept therapy is associated with a significantly greater number of reported uveitis cases in comparison with infliximab and adalimumab in 2 medication side effect registries. These results are consistent with previous studies and suggest that this relationship is drug specific and not related to TNF inhibitors as a whole. However, our findings do not support the use of infliximab over etanercept; rather, if a patient develops uveitis during etanercept therapy, then a change to infliximab may be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-lhle, E., Kellner, H., Krause, A., Schneider, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08215-6 · Cited by 1,261
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Gritz, D. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.06.014 · Cited by 847
Ina, K., Itoh, J., Fukushima, K., Kusugami, K., Yamaguchi, T., Kyokane, K., Imada, A., Binion, D. G., Musso, A., West, G. A., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.1081 · Cited by 345
Smith, J. A., Thompson, D. J. S., Whitcup, S. M., Suhler, E., Clarke, G., Smith, S., Robinson, M., Kim, J., & Barron, K. S. (2005) · Arthritis Care & Research · doi:10.1002/art.20904 · Cited by 308
Suhler, E. B. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.7.903 · Cited by 306
Etanercept therapy in children with treatment-resistant uveitis
Reiff, A., Takei, S., Sadeghi, S., Stout, A., Shaham, B., Bernstein, B., Gallagher, K., & Stout, T. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1411::aid-art235>3.0.co;2-o · Cited by 298
Adalimumab in the therapy of uveitis in childhood
Biester, S., Deuter, C., Michels, H., Haefner, R., Kuemmerle-Deschner, J., Doycheva, D., & Zierhut, M. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.103721 · Cited by 294
Tumour necrosis factor α inhibitors in the treatment of childhood uveitis
Saurenmann, R. K., Levin, A. V., Rose, J. B., Parker, S., Rabinovitch, T., Tyrrell, P. N., Feldman, B. M., Laxer, R. M., Schneider, R., & Silverman, E. D. (2006) · Rheumatology · doi:10.1093/rheumatology/kel030 · Cited by 216
Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate
Foster, C. S. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.4.437 · Cited by 213
Differential Effectiveness of Etanercept and Infliximab in the Treatment of Ocular Inflammation
Galor, A., Perez, V. L., Hammel, J. P., & Lowder, C. Y. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.04.038 · Cited by 210
Tynjälä, P., Lindahl, P., Honkanen, V., Lahdenne, P., & Kotaniemi, K. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.058248 · Cited by 206
Cytokine mRNA levels in rat ocular tissues after systemic endotoxin treatment.
Planck, S. R., Huang, X. N., Robertson, J. E., & Rosenbaum, J. T. (1994) · PubMed · Cited by 143
Self-citationZou, J., Rudwaleit, M., Brandt, J., Thiel, A., Braun, J., & Sieper, J. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.6.561 · Cited by 129
Tumour necrosis factor inhibitors
Nash, P. T., & Florin, T. H. (2005) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06998.x · Cited by 126
Does etanercept induce uveitis?
Reddy, A. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.7.925 · Cited by 121
Zou, J., Rudwaleit, M., Brandt, J., Thiel, A., Braun, J., & Sieper, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10847 · Cited by 103
Fleischmann, R., Iqbal, I., Nandeshwar, P., & Quiceno, A. (2002) · Drug Safety · doi:10.2165/00002018-200225030-00004 · Cited by 93
Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα
Baeten, D., Damme, N. V., den Bosch, F. V., Kruithof, E., Vos, M. D., Mielants, H., Veys, E. M., & Keyser, F. D. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.8.750 · Cited by 93
Braun, J., Keyser, F. D., Brandt, J., Mielants, H., Sieper, J., & VEYS, E. M. (2001) · Current Opinion in Rheumatology · doi:10.1097/00002281-200107000-00001 · Cited by 72
Diverse effects of infliximab and etanercept on T lymphocytes
Sieper, J., & Brande, J. V. D. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.01.006 · Cited by 49
Savion, S., Oddo, S., Grover, S., & Caspi, R. R. (1994) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)90144-9 · Cited by 33
Side effects of anti-TNFa therapy in juvenile idiopathic arthritis
Pontikaki, I., Gerloni, V., Gattinara, M. V., Lurati, A., Salmaso, A., Marco, G. D., Teruzzi, B. L., Valcamonica, E., & Fantini, F. (2011) · Reumatismo · doi:10.4081/reumatismo.2006.31 · Cited by 25
Cited by
Levy-Clarke, G., Jabs, D. A., Read, R. W., Rosenbaum, J. T., Vitale, A., & Van Gelder, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.048 · Cited by 483
Self-citationBritish Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
Smith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D. A., Finlay, A. Y., Griffiths, C. E. M., Jackson, K., McHugh, N. J., et al. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09505.x · Cited by 464
Autoimmune diseases induced by biological agents
Ramos-Casals, M., Roberto-Perez-Alvarez, Diaz-Lagares, C., Cuadrado, M.-J., & Khamashta, M. A. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.10.003 · Cited by 323
Rudwaleit, M., Rødevand, E., Holck, P., Vanhoof, J., Kron, M., Kary, S., & Kupper, H. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092585 · Cited by 297
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
Dick, A. D., Rosenbaum, J. T., Al-Dhibi, H. A., Belfort, R., Brézin, A. P., Chee, S. P., Davis, J. L., Ramanan, A. V., Sonoda, K.-H., Carreño, E., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.017 · Cited by 285
Self-citation
Metadata
- Authors
- Lim, L. L., Fraunfelder, F. W., & Rosenbaum, J. T.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-09-28
- Volume
- 56
- Issue
- 10
- Pages
- 3248-3252
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2064877272
- Cited by
- 315
- References
- 27
- FWCI
- 16.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.